Trial Outcomes & Findings for Comparison of Rimegepant and Placebo for Pain in IBS (NCT NCT06221111)
NCT ID: NCT06221111
Last Updated: 2026-05-22
Results Overview
The change in daily abdominal pain scores will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.
COMPLETED
PHASE2
39 participants
Baseline; Day 28
2026-05-22
Participant Flow
39 participants were enrolled in the study, 10 of which were excluded prior to randomization due to screening failing and 5 of which were excluded prior to randomization due to withdrawing.
Participant milestones
| Measure |
Rimegepant
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
12
|
|
Overall Study
COMPLETED
|
12
|
12
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Comparison of Rimegepant and Placebo for Pain in IBS
Baseline characteristics by cohort
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Total
n=24 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
38 years
n=2 Participants
|
38 years
n=4 Participants
|
38.0 years
n=6 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=2 Participants
|
7 Participants
n=4 Participants
|
17 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=2 Participants
|
5 Participants
n=4 Participants
|
7 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
12 Participants
n=2 Participants
|
12 Participants
n=4 Participants
|
24 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
12 Participants
n=2 Participants
|
12 Participants
n=4 Participants
|
24 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Region of Enrollment
United States
|
12 participants
n=2 Participants
|
12 participants
n=4 Participants
|
24 participants
n=6 Participants
|
PRIMARY outcome
Timeframe: Baseline; Day 28The change in daily abdominal pain scores will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Abdominal Pain Scores
|
-12 score on a scale
Interval -16.9 to -6.4
|
-22.6 score on a scale
Interval -30.3 to -8.1
|
SECONDARY outcome
Timeframe: Baseline; Day 28The change in bowel movement frequency measured by the number of bowel movements a participant reported having each day from baseline through day 28.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Bowel Movement Frequency
|
-0.2 bowel movements per day
Interval -0.8 to 0.0
|
-0.9 bowel movements per day
Interval -1.0 to -0.4
|
SECONDARY outcome
Timeframe: Baseline; Day 28The change in rectal compliance threshold defined as the change in pressure at half maximum volume (Pr 1/2) measured using a rectal barostat device. The rectal barostat device is a rectal catheter with a polyethylene bag attached (length 22 cm; capacity 600 ml) that is inserted into the rectum and connected to a barostat. The bag is unfolded by inflation with 75 ml of air, followed by complete deflation. After a 10 minute recovery period, the pressure is increased from 0 mmHg in steps of 4 mmHg for 15 seconds per step until 20 mmHg is reached. The observed volume/maximum observed volume will be used to obtain a pressure corresponding to half the maximum observed volume. A calculation of the pressures corresponding to the volumes just above and just below the half maximum volume will provided the specific pressure (Pr 1/2) corresponding to one half of the maximum observed volume.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Rectal Compliance
|
2.1 mmHg
Interval -1.3 to 7.0
|
-0.1 mmHg
Interval -4.2 to 2.2
|
SECONDARY outcome
Timeframe: Baseline; Day 28The change in rectal sensation pain threshold in response to the pressure in the balloon escalating from 0 mmHg to 44 mmHg at 4 mmHg stepwise increases measured using the 100-mm Visual analog scale (VAS). The scale ranges from (unnoticeable) to (unbearable). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "unnoticeable" on the left, and "unbearable" on the right. Participants will identify their level of pain by indicating a point on the line between each end. That point will be measured from the "unnoticeable" end, and the number of millimeters will be reported as the pain score. Total scores range from 0 to 100 with higher scores indicating worse pain.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Rectal Sensation Pain Threshold
|
4.0 score on a scale
Interval -4.0 to 10.0
|
0.0 score on a scale
Interval -4.0 to 4.0
|
SECONDARY outcome
Timeframe: Baseline; Day 28The change in rectal sensation ratings in response to 24 mmHg and 36 mmHg distensions measured using the 100-mm Visual analog scale (VAS). The scale ranges from (unnoticeable) to (unbearable). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "unnoticeable" on the left, and "unbearable" on the right. Participants will identify their sensation of pain, urgency and gas levels by indicating a point on the line between each end. That point will be measured from the "unnoticeable" end, and the number of millimeters will be reported as the pain, gas and urgency scores. Total scores range from 0 to 100 with higher scores indicating worsening sensation of pain, urgency and gas.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Gas at 24 mmHg
|
-23.5 score on a scale
Interval -35.0 to -0.5
|
-7 score on a scale
Interval -21.0 to 14.0
|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Urgency at 24 mmHg
|
-13.5 score on a scale
Interval -32.0 to -7.0
|
-6 score on a scale
Interval -14.0 to -0.5
|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Pain at 24 mmHg
|
-11 score on a scale
Interval -29.0 to 1.0
|
4 score on a scale
Interval -2.0 to 10.0
|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Gas at 36 mmHg
|
-1 score on a scale
Interval -26.0 to 6.0
|
-1 score on a scale
Interval -6.0 to 13.0
|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Urgency at 36 mmHg
|
-12 score on a scale
Interval -27.0 to 2.0
|
0.5 score on a scale
Interval -5.0 to 8.0
|
|
Change in Rectal Sensation Ratings in Response to 24 and 36 mmHg Distensions
Pain at 36 mmHg
|
-12 score on a scale
Interval -20.0 to 9.0
|
3 score on a scale
Interval -1.0 to 8.0
|
SECONDARY outcome
Timeframe: Day 28Percentage of solids moved from the stomach to the small intestine (gastric emptying) at 4 hours on Day 28.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Gastric Emptying of Solids
|
0.9 percentage of solids emptied
Interval 0.8 to 1.0
|
0.9 percentage of solids emptied
Interval 0.7 to 1.0
|
SECONDARY outcome
Timeframe: Baseline; Day 28The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken at 4, 6, 8, 24, and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Change in Colonic Transit at 24 Hours
|
-0.3 units on a scale
Interval -1.2 to 1.6
|
0.4 units on a scale
Interval -0.3 to 1.1
|
SECONDARY outcome
Timeframe: Day 28The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken at 4, 6, 8, 24, and 48 hours. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Colonic Transit at 48 Hours
|
4.7 units on a scale
Interval 2.7 to 5.0
|
4.3 units on a scale
Interval 2.8 to 4.9
|
SECONDARY outcome
Timeframe: Baseline; Day 28; Day 56Irritable Bowel Syndrome Quality of Life (IBS-QOL) is a self-reported measure used to assess the impact of irritable bowel syndrome (IBS) on a participant's quality of life. The IBS-QOL consists of 34 items that cover eight distinct sub-domains, including emotional well-being, social functioning, dietary habits and intimate relationships. Each item is rated on a 5-point Likert scale, ranging from 1 (not at all) to 5 (a great deal). The raw scores are converted to a 0-100 scale where higher scores indicate a better quality of life.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Irritable Bowel Syndrome Quality of Life
Day 28
|
75 score on a scale
Interval 57.7 to 83.1
|
73.2 score on a scale
Interval 64.3 to 89.3
|
|
Irritable Bowel Syndrome Quality of Life
Baseline
|
61.4 score on a scale
Interval 46.3 to 70.6
|
74.3 score on a scale
Interval 53.7 to 84.9
|
|
Irritable Bowel Syndrome Quality of Life
Day 56
|
72.8 score on a scale
Interval 51.5 to 89.7
|
75 score on a scale
Interval 50.0 to 80.9
|
SECONDARY outcome
Timeframe: Day 1; Day 28The number of participants who experienced an Adverse Event.
Outcome measures
| Measure |
Rimegepant
n=12 Participants
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 Participants
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Number of Participants Who Experienced an Adverse Event
|
3 Participants
|
3 Participants
|
Adverse Events
Rimegepant
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Rimegepant
n=12 participants at risk
* Rimegepant 75mg oral dissolving tablet (ODT)
* Formulation and Dosing as FDA-approved for Migraine Prevention: 75 mg Every Other Day (EOD) for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
Placebo
n=12 participants at risk
Placebo ODT appearing identical to the experimental formulation and administered every other day for 4 weeks/30 days
Rimegepant 75 MG \[Nurtec\]: placebo controlled trial
|
|---|---|---|
|
Gastrointestinal disorders
Retching
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Nervous system disorders
Migraine
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Gastrointestinal disorders
Nausea
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Gastrointestinal disorders
Vomiting
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Infections and infestations
Rash
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Nervous system disorders
Postural Orthostatic Tachycardia Syndrome
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
8.3%
1/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
|
Gastrointestinal disorders
Change of bowel habit (reduced frequency)
|
16.7%
2/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
0.00%
0/12 • Adverse events were collected from the date the participant received the first dose of medication through the washout period, approximately 56 days.
Adverse events were collected through non-leading questions, signs and symptoms detected during examination, laboratory evaluations, by observations of study personnel and by spontaneous reports from participants.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place